worth a punt, page-16

No worries Austrian. OSL does need money for the registration study but we don't know just yet how much they need and how they are going to do it. I think we can rule out a rights issue as the biotech sector is doing really well at the moment and the share price has been on a tremendous run. My guess is either a placement to private/institutional investors or a licensing deal with a big pharmaceutical company. Presumbaly the cost of the registration study is less than what would be required for a similar study for a vaccine. People like Malmanu would have a better idea. Cheers and good luck.